<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5484-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KLACID 500MG IV POWDER FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DELPHARM REIMS S.A.S" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DELPHARM REIMS S.A.S
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Klacid Intravenous contains the active ingredient clarithromycin. Klacid belongs to a group of medicines called macrolide antibiotics. Antibiotics stop the growth of bacteria (bugs) that cause infections.</p><p>Klacid Intravenous is used whenever an intravenous (injection into the vein) antibiotic is required to treat severe infections or, alternatively, if a patient cannot swallow Klacid tablets.</p><p>It is used to treat infections such as:</p><p>1. Chest infections such as bronchitis and pneumonia<br />2. Throat and sinus infections<br />3. Skin and tissue infections</p><p>Klacid Intravenous is indicated in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not receive Klacid Intravenous if you;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; know that you are&nbsp;<strong>allergic</strong>&nbsp;to clarithromycin, other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients in Klacid Intravenous.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called ergot alkaloid tablets (e.g. ergotamine or dihydroergotamine) or use ergotamine inhalers for migraine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride (for stomach disorders) or pimozide (for mental health problems) as combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult your doctor for advice on alternative medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines which are known to cause serious disturbances in heart rhythm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to lower levels of cholesterol (a type of fat) in the blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking oral midazolam (a sedative).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have abnormally low levels of potassium in your blood (hypokalaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have&nbsp;<strong>severe</strong>&nbsp;liver disease with kidney disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or someone in your family has a history of heart rhythm disorders (ventricular cardiac arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG, electrical recording of the heart) called &quot;long QT syndrome&quot;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking colchicine (usually taken for gout).</p><p><strong>Take special care with Klacid Intravenous</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have abnormally low levels of magnesium in your blood (hypomagnesaemia) consult your doctor before being given Klacid Intravenous.</p><p><strong>Klacid Intravenous is not suitable for use in children under 12 years of age.</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before being given Klacid Intravenous;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems (e.g. heart disease, heart failure, an unusually slow heart rate, or low levels of magnesium in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any liver or kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or are prone to, fungal infections (e.g. thrush)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast feeding</p><p><strong>Other medicines and Klacid Intravenous</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines as your dose may need to be changed or you may need to have regular tests performed:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin, quinidine or disopyramide (for heart problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin (for thinning the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins, and used to lower levels of cholesterol (a type of fat) in the blood). Statins can cause rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage) and signs of myopathy (muscle pain or muscle weakness) should be monitored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; theophylline (used in patients with breathing difficulties such as asthma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cilostazol (for poor circulation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methylprednisolone (a corticosteroid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vinblastine (for treatment of cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, sirolimus and tacrolimus (immune suppressants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the treatment of HIV)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of certain bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolterodine (for overactive bladder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, amlodipine, diltiazem (for high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#39;s Wort (a herbal product used to treat depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quetiapine or other antipsychotic medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other macrolide medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lincomycin and clindamycin (lincosamides &mdash; a type of antibiotic)</p><p>Klacid Intravenous does not interact with oral contraceptives.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist before receiving the medicine as the safety of clarithromycin in pregnancy or breast-feeding is not known.</p><p><strong>Driving and Using Machines:</strong></p><p>Klacid Intravenous may make you feel dizzy or drowsy. If they affect you in this way do not drive, operate machinery or do anything that requires you to be alert</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Klacid Intravenous is prepared by your doctor or nurse by dissolving the powder in the vial in sterile water. The solution obtained is added to a larger volume of sterile liquid. Klacid Intravenous is given to you slowly through a needle, into your vein over a period of at least an hour.</p><p>The usual dose of Klacid Intravenous for adults and children over 12 years is 1.0g per day, split into two doses, for 2 to 5 days. Your doctor will work out the correct dose for you.</p><p>Children under 12 years should not be given Klacid Intravenous. Your doctor will prescribe another suitable medicine for your child.</p><p>If a child accidentally swallows some of this medicine, seek medical advice urgently.</p><p><strong>If you are given more Klacid Intravenous than you should have</strong></p><p>As Klacid Intravenous is given to you by a doctor, an overdose is unlikely but symptoms may include vomiting and stomach pains.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Klacid Intravenous can cause side effects although not everybody gets them.</p><p>If you suffer from any of the following at any time during your treatment tell your doctor immediately as your treatment may need to be stopped:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may occur over two months after treatment with clarithromycin, in which case you should still contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rash, difficulty breathing, fainting or swelling of the face and throat. This is a sign that you may have developed an allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite. These may be signs that your liver may not be working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions such as blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain or weakness known as rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage).</p><p>Common side effects (may affect up to 1 in 10 people) include;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation, tenderness or pain at the site of the injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in the way the liver works</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>Uncommon side effects (may affect up to 1 in 100 people) include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, redness or itchiness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral or vaginal &#39;thrush&#39; (a fungal infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach and intestines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of the levels of blood platelets (blood platelets help stop bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in white blood cells (leukopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in neutrophils (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of eosinophils (white blood cells involved in immunity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exaggerated immune response to a foreign agent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety, nervousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, tiredness, dizziness or shaking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears or hearing loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma: lung disease associated with tightening of air passages, making breathing difficult</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot that causes sudden blockage in a lung artery (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; )</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the gullet (oesophagus) and lining of the stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the tongue, mouth and lips</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating, constipation, wind, burping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situation where the bile (fluid made by the liver and stored in the gallbladder) cannot flow from the gallbladder to the duodenum (cholestasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin characterized by the presence of the bullae which are filled with fluid, itchy and painful rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, muscle pain or loss of muscle tissue. If you suffer from myasthenia gravis (a condition in which the muscles become weak and tire easily), clarithromycin may worsen these symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised abnormal kidney and liver function blood test and raised blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, tired and having no energy</p><p>Not known side effects (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the colon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection of the outer layers of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the level of certain blood cells (which can make infections more likely or increase the risk of bruising or bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the lips and eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or over-excitement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paraesthesia, more commonly known as &#39;pins and needles&#39;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of taste or smell or inability to smell properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of blood (haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discolouration of the tongue or teeth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the levels of products made by the liver, inflammation of the liver or an inability of the liver to function properly (you may notice yellowing of the skin, dark urine, pale stools or itchiness of the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome: skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rare allergic skin reactions which cause severe illness with ulceration of the mouth, lips and skin which causes severe illness with rash, fever and inflammation of internal organs (DRESS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the levels of products produced by the kidney, inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling or puffiness in the face, abdomen, thighs or ankles or problems with urination)</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p><strong>-National Pharmacovigilance Center (NPC)</strong></p><p><strong>o Fax: +966-11-205-7662</strong></p><p><strong>o SFDA Call Center: 19999</strong></p><p>o <strong>E-mail: npc.drug@sfda.gov.sa</strong></p><p>o <strong>Website: https://ade.sfda.gov.sa</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep out of the sight and reach of children</strong></p><p>Do not use after the expiry date on the carton and vial.</p><p>Do not store above 30&deg;C.</p><p>The initial solution after reconstitution may be stored for 24 hours between 2 and 8 C (in the refrigerator)</p><p>The final solution after dilution may be stored for 24 hours between 2 and 8 C (in the refrigerator) or for 6 hours at a temperature below 25 C&nbsp;</p><p>&nbsp;</p><p><strong>Shelf Life</strong></p><p>36 months</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Klacid Intravenous contains the active ingredient clarithromycin.</p><p>The other ingredients are; lactobionic acid and sodium hydroxide.</p><p>This medicinal product contains less than 23mg sodium (1mmol) per 500mg i.e. essentially &quot;sodium-free&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Klacid Intravenous is available in vials containing 500mg of clarithromycin as the active ingredient. When made up with Water for Injections, each millilitre (ml) of solution contains 2mg of clarithromycin.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder -</strong></p><p>Abbott Laboratories Limited</p><p>Abbott House</p><p>Vanwall Business Park</p><p>Vanwall Road</p><p>Maidenhead Berkshire</p><p>SL6 4XE</p><p>UK</p><p><strong>Manufacturer -</strong></p><p>FAMAR L&#39;Aigle Usine St Remy<br />Rue de L&#39;Isle<br />28380 Saint Remy sur Avre<br />France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كلاسيد للاستعمال الوريدي على المكوّن الفعّال كلاريثروميسين. ينتمي كلاسيد إلى مجموعة أدوية يطلق عليها المضادات الحيوية الماكروليدية. المضادات الحيوية توقف نمو البكتيريا (الجراثيم) المسببة للعدوى.</p><p dir="RTL">يستخدم كلاسيد للاستعمال الوريدي حينما يكون المضاد الحيوي الوريدي (الحقن داخل الوريد) ضروريًا لعلاج حالات العدوى الحادة أو، بدلاً من ذلك، إذا لم يستطع المريض ابتلاع أقراص كلاسيد.</p><p dir="RTL">يستخدم كلاسيد للاستعمال الوريدي لعلاج حالات عدوى مثل:</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الصدر مثل الالتهاب الشعبي والالتهاب الرئوي</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . عدوى الحلق والجيوب الأنفية</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;عدوى الجلد والأنسجة</p><p dir="RTL">يُوصَف كلاسيد للاستعمال الوريدي للبالغين والأطفال من عمر 12 عامًا وأكبر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يمنع استخدام كلاسيد للاستعمال الوريدي في حالة؛</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود <strong>حساسية</strong> من الكلاريثروميسين أو غيرها من المضادات الحيوية الماكروليدية مثل الاريثروميسين أو أزيثروميسين أو أي مكوّن آخر من مكونات كلاسيد للاستعمال الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقي أدوية تسمى قلويدات الإرجوت (مثل الإرجوتامين أو ثنائي هيدرو إرجوتامين) أقراص أو استخدام أجهزة استنشاق الإرجوتامين لعلاج الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أدوية تسمى تيرفينادين أو أستيميزول (يكثر استخدامها لعلاج حمى القش أو الحساسية) أو سيسابريد (لعلاج اضطرابات المعدة) أو بيموزيد (لمشكلات الصحة العقلية)؛ لأن استخدامها بالتزامن مع هذا الدواء يمكن أن يؤدي أحيانًا إلى اضطرابات بالغة في انتظام ضربات القلب. لذا؛ يوصى باستشارة الطبيب لمعرفة الأدوية البديلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناوُل أدوية أخرى تعرف بأنها تسبب اضطرابات خطيرة في انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول اللوفاستاتين أو سيمفاستاتين (مثبطات الأنزيم المختزل HMG-CoA، والمعروفة باسم الستاتينات &nbsp;والتي تستخدم لتخفيض مستويات الكوليسترول (نوع من الدهون) في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الميدازولام عن طريق الفم (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض غير الطبيعي لمستويات البوتاسيوم بالدم (نقص بوتاسيوم الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بمرض <strong>خطير</strong> بالكبد مصحوبًا بمرض في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أو أحد أفراد عائلتك تاريخ من اضطرابات نظم القلب (اضطراب نظم القلب البطيني ، بما في ذلك تورساد دي بوانت) أو شذوذ في التخطيط الكهربائي للقلب (ECG، وهوالتسجيل الكهربي للقلب) تسمى &quot;متلازمة QT طويلة&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أدوية تسمى تيكاجريلور أو رانولازين (لعلاج النوبة القلبية أو آلام الصدر أو الذبحة الصدرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الكولشيسين (يُستعمل عادةً لعلاج النقرس).</p><p dir="RTL"><strong>توخِ بالغ الحذر عند استخدام كلاسيد للاستعمال الوريدي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الانخفاض غير الطبيعي لمستويات المغنيسيوم في الدم (نقص مغنيسيوم الدم)، استشر الطبيب قبل إعطائك كلاسيد للاستعمال الوريدي.</p><p dir="RTL"><strong>كلاسيد للاستعمال الوريدي غير مناسب للاستخدام في الأطفال الذين تقل أعمارهم عن 12 عامًا.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى الطبيب أو الصيدلي قبل إعطائك كلاسيد للاستعمال الوريدي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في القلب (مثل مرض بالقلب أو قصور بالقلب، أو بطء غير معتاد في معدل ضربات القلب، أو انخفاض مستويات المغنيسيوم في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشكلات بالكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا، أو عرضة للإصابة، بعدوى فطرية (مثل مرض القلاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو ترضعين رضاعةً طبيعية</p><p dir="RTL"><strong>الأدوية الأخرى وكلاسيد للاستعمال الوريدي</strong></p><p dir="RTL">تحدث إلى الطبيب أو الصيدلي إذا كنت تتناول حاليًا أو تناولت مؤخرًا أو قد تتناول مستقبلاً أي أدوية أخرى؛ لأنه ربما يلزم تغيير الجرعة أو ربما تحتاج إلى إجراء فحوصات بصفة دورية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين أو كينيدين أو ديسوبيراميد (لمشكلات القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين (لتسييل الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين أو فالبروات أو فينوباربيتال أو فينيتوين (للصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتين، رسيوفاستاتين (مثبطات الأنزيم المختزل HMG-CoA، والمعروفة باسم الستاتينات ، وتستخدم لتخفيض مستويات الكوليسترول (نوع من الدهون) في الدم). يمكن أن تتسبب الستاتينات في انحلال الرُبَيدات (حالة مرضية تسبب تكسيرًا في أنسجة العضلات والذي يمكن أن يؤدي إلى تلف الكلى) كما ينبغي مراقبة علامات الاعتلال العضلي (ألم أو ضعف في العضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناتيجلينيد أو بيوجليتازون أو ريباجلينيد أو روزيجليتازون أو الأنسولين (المستخدم لتخفيض مستويات الجلوكوز في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكلازايد أو غليمبريد (سلفونيل يوريا المستخدم في علاج داء السكري من النوع الثاني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيلين (المستخدم في علاج المرضى المصابين بصعوبات في التنفس مثل الربو)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريازولام، ألبرازولام، الميدازولام عن طريق الفم أو الوريد (مهدئات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (لضعف الدورة الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل بريدنيزولون (أحد السترويدات القشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينبلاستين (لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين وسيروليموس وتاكروليموس (مثبطات المناعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إترافيرين، إيفافيرنز، نيفيرابين، ريتونافير، زيدوفودين، أتازنافير، ساكوينافير (عقاقير مضادة للفيروسات تستخدم في علاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين، ريفامبيسين، ريفابنتين، فلوكونازول، ايتراكونازول (يستخدم في علاج بعض حالات عدوى البكتيريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولتيرودين (لفرط نشاط المثانة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، أملوديبين، ديلتيازيم (لارتفاع ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدنافيل وفاردنافيل وتادالافيل (للعجز الجنسي لدى الذكور البالغين أو للاستخدام في ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الأوعية الدموية في الرئة))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون العشبية (منتج عشبي يستخدم لعلاج الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كويتيابين أو الأدوية الأخرى المضادة للذهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الماكروليدية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لينكوميسين وكليندامايسين (لينكوساميدس - أحد أنواع المضادات الحيوية)</p><p dir="RTL">لا يتفاعل كلاسيد للاستعمال الوريدي مع موانع الحمل التي تعطى عن طريق الفم .</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مُرضعة، أو تعتقدين بأنكِ حامل أو تخططين لحدوث الحمل، فاستشيري طبيبك أو الصيدلي قبل تلقي الدواء؛ إذ إن سلامة استخدام الكلاريثروميسين في أثناء الحمل أو الرضاعة الطبيعية غير معروفة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">قد يؤدي كلاسيد للاستعمال الوريدي إلى شعورك بالدوار أو النعاس. إذا كانت هذه الأدوية تؤثر فيك بهذه الطريقة فتجنّب قيادة السيارات أو تشغيل الآلات أو القيام بأي شيء يتطلب منك أن تكون في حالة انتباه.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحضَّر كلاسيد للاستعمال الوريدي عن طريق الطبيب أو الممرضة من خلال إذابة المسحوق الموجود في الزجاجة &nbsp;بمياه معقمة. ويُضاف المحلول الذي يتم الحصول عليه إلى مقدار أكبر من السائل المعقم. ثم يُعطى كلاسيد للاستعمال الوريدي ببطء بواسطة إبرة، داخل الوريد في غضون فترة لا تقل عن ساعة.</p><p dir="RTL">الجرعة المعتادة من كلاسيد للاستعمال الوريدي للكبار والأطفال البالغين أكثر من 12 عامًا هي 1.0 جرام يوميًا، تقسّم إلى جرعتين، لمدة يومين إلى 5 أيام. وسيحدد الطبيب الجرعة الصحيحة لك.</p><p dir="RTL">لا ينبغي إعطاء الأطفال دون سن 12 عامًا كلاسيد للاستعمال الوريدي. وسيصف طبيبك دواءً آخر مناسب للطفل.</p><p dir="RTL">إذا ابتلع الطفل بطريق الخطأ بعضًا من هذا الدواء، فاطلب المشورة الطبية على وجه السرعة.</p><p dir="RTL"><strong>إذا تم إعطاؤك جرعة كلاسيد للاستعمال الوريدي أكبر مما ينبغي</strong></p><p dir="RTL">بما أن كلاسيد للاستعمال الوريدي يتم إعطاؤه لك بواسطة الطبيب، فمن غير المحتمل أخذ جرعة زائدة منه، ولكن الأعراض قد تشمل القيء وآلامًا في المعدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب كلاسيد للاستعمال الوريدي مثل جميع الأدوية في حدوث آثار جانبية، على الرغم من عدم تعرض جميع المرضى لها.</p><p dir="RTL">إذا كنت تعاني من أي مما يلي في أي وقت أثناء العلاج، فأخبر طبيبك فورًا فربما يلزم إيقاف العلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد أو لفترات طويلة، والذي ربما يحتوي على دم أو مخاط. قد يحدث الإسهال في غضون مدة شهرين من العلاج بالكلاريثروميسين، وفي هذه الحالة ينبغي لك زيارة الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، صعوبة في التنفس، إغماء أو تورّم في الوجه والحنجرة. وهذه علامة على احتمال إصابتك برد فعل تحسسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (اليرقان)، تهيّج الجلد، براز شاحب، بول داكن، ألم بالبطن أو فقدان الشهية. قد تكون هذه علامات على أن الكبد قد لا يعمل بشكل صحيح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل جلدية حادة مثل بثور بالجلد والفم والشفتين والعينين والأعضاء التناسلية (أعراض رد فعل تحسسي نادر يسمى متلازمة ستيفنز جونسون/تقشر الأنسجة المتموتة البشروية التسممي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام أو ضعف في العضلات يعرف باسم انحلال الربيدات (وهي حالة تسبب اتكسيرا بالأنسجة العضلية والذي يمكن أن يؤدي إلى تلف بالكلى).</p><p dir="RTL">الآثار الجانبية الشائعة (يمكن أن يتأثر بها ما يصل إلى 1 من كل 10 أشخاص) تتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو ألم في موقع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسّع الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في المعدة مثل الشعور بالغثيان، القيء، آلام في المعدة، عسر الهضم، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في طريقة عمل الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرّق</p><p dir="RTL">الآثار الجانبية غير الشائعة (يمكن أن يتأثر بها ما يصل إلى 1 من كل 100 شخص) تتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم، احمرار أو حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;قلاع&quot; فموي أو مهبلي (عدوى فطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفائح الدموية (تساعد الصفائح الدموية على وقف النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (نقص الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض العدلات (قلة العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيّبس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة مفاجئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة اليوزينيات (خلايا الدم البيضاء المشاركة في المناعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الاستجابة المناعية بسبب عامل خارجي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية أو فقدانها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق وعصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس أو تعب أو دوخة أو رعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير إرادية بالعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الأذنين أو فقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو تغييرات في ضربات القلب مثل الخفقان أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو: مرض رئوي يرتبط بضيق الممرات الهوائية؛ مما يجعل التنفس صعبًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط دموي يسبب انسدادًا مفاجئًا في شريان الرئة (الانسداد الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المريء وبطانة المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شرجي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب اللسان والفم والشفتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ، إمساك، غازات، تجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة يتعذر فيها تدفق الصفراء (سائل ينتجه الكبد ويخزّن في المرارة) من المرارة إلى الإثني عشر (ركود صفراوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب جلدي يتميز بوجود فقاعات مليئة بالسوائل، حكة وطفح جلدي مؤلم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات، آلام في العضلات أو فقدان الأنسجة العضلية. إذا كنت تعاني من الوهن العضلي الوبيل (حالة تصبح فيها العضلات ضعيفة ومجهدة بسهولة)، فإن كلاريثروميسين قد يفاقم هذه الأعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبار الدم لوظائف الكبد والكلى وارتفاع نتائج اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف، والتعب وعدم وجود الطاقة</p><p dir="RTL">آثار جانبية غير معروفة (يتعذر تقدير معدل حدوثها من البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتيرية بالطبقات الخارجية من الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بعض خلايا الدم (والتي يمكن أن يزيد من احتمال حدوث العدوى أو زيادة خطر الكدمات أو النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم في الشفتين والعينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك، فقدان الاتجاهات، هلوسة (رؤية أشياء)، تغيير في الشعور بالواقع أو ذعر، اكتئاب، أحلام غير طبيعية أو كوابيس وهوس (شعور بالابتهاج أو الإفراط في الإثارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج (نوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مَذَل، أكثر شيوعًا باسم &quot;وخز أو تخدر&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق أو الشم أو عدم القدرة على الشم بشكل صحيح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من اضطراب ضربات القلب (تورساد دي بوانت ، تسرع القلب البطيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الدم (نزيف دموي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون اللسان أو الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في مستويات العناصر التي يفرزها الكبد، التهاب الكبد أو عدم قدرة الكبد على العمل بشكل صحيح (قد تلاحظ اصفرار الجلد، بولاً داكنًا، برازًا شاحبًا أو حكة في الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون: حالة جلدية تسبب بثورًا وقروحًا مؤلمة بالجلد والأغشية المخاطية، خاصة في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية نادرة بالجلد تسبب مرضًا بالغًا مصحوبًا بتقرّح الفم والشفتين والجلد، مما يسبب مرضًا شديدًا مع طفح جلدي وحمى والتهاب الأعضاء الداخلية (DRESS)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في مستويات العناصر التي تفرزها الكلى، التهاب الكلى أو عدم قدرتها على العمل بشكل صحيح (قد تلاحظ تعبًا أو تورّمًا أو انتفاخًا في الوجه أو البطن أو الفخذين أو الكاحلين أو مشكلات في التبول)</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي آثار جانبية، فتحدث مع طبيبك أو الصيدلي. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحفظ بعيدًا عن متناول ومرأى الأطفال</strong></p><p dir="RTL">لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الكرتونية والزجاجة .</p><p dir="RTL">لا يخزن في درجة حرارة أعلى من ۳٠ درجة مئوية</p><p dir="RTL">يجوز تخزين المحلول الأولي بعد التحضير لمدة 24 ساعة بين 2 و8 درجات مئوية (في الثلاجة)</p><p dir="RTL">يجوز تخزين المحلول النهائي بعد التخفيف لمدة 24 ساعة بين 2 و8 درجات مئوية (في الثلاجة) أو لمدة 6 ساعات عند درجة حرارة أقل من 25 درجة مئوية&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>فترة الصلاحية</strong></p><p dir="RTL">36 شهرًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي كلاسيد للاستعمال الوريدي على المكوّن الفعّال كلاريثروميسين.</p><p dir="RTL">المكونات الأخرى هي؛ حمض اللاكتوبيونيك وهيدروكسيد الصوديوم.</p><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 23 ملجم من الصوديوم (1 مليمول) لكل ٥٠٠ ملجم، بعبارة أخرى &quot;خالٍ من الصوديوم&quot; تمامًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر كلاسيد للاستعمال الوريدي في زجاجة &nbsp;تحتوي على ٥٠٠ ملجم من الكلاريثروميسين كعنصر نشط. عند إذابته بالماء للحقن، فإن كل ملليلتر (مل) من المحلول يحتوي على 2 ملجم من كلاريثروميسين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق -</strong></p><p dir="RTL">&nbsp;مختبرات أبوت المحدودة</p><p dir="RTL">أبوت هاوس</p><p dir="RTL">&nbsp;فانوال بزنس بارك</p><p dir="RTL">طريق فانوال</p><p dir="RTL">مايدنهيد بيركشاير</p><p dir="RTL">SL6 4XE</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL"><strong>الجهة المصنعة -</strong></p><p dir="RTL">FAMAR L&#39;Aigle Usine St Remy<br />Rue de L&#39;Isle<br />28380 Saint Remy sur Avre<br />France</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Klacid IV 500 mg, Powder for Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient: Clarithromycin 500mg/vial
One vial contains 739.5 mg clarithromycin lactobionate, corresponding to 500mg clarithromycin.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilised powder for reconstitution to give a solution for IV administration.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Klacid IV 500 mg is indicated in adults and children 12 years and older.</p><p>Klacid IV 500 mg is indicated whenever parenteral therapy is required for treatment of infections caused by susceptible organisms in the following conditions;</p><p>- Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).</p><p>- Upper respiratory tract infections for example, sinusitis and pharyngitis.</p><p>- Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For intravenous administration only.</p><p>Intravenous therapy may be given for 2 to 5 days in the very ill patient and should be changed to oral clarithromycin therapy whenever possible as determined by the physician.</p><p><strong>Adults:</strong>&nbsp;The recommended dosage of Klacid IV 500 mg is 1.0 gram daily, divided into two 500mg doses, appropriately diluted as described below.</p><p><strong>Children older than 12 years:&nbsp;</strong>As for adults.</p><p><strong>Children under 12 years:&nbsp;</strong>Use of Klacid IV 500 mg is not recommended for children younger than 12 years. Use Klacid Paediatric Suspension.</p><p><strong>Elderly:</strong>&nbsp;As for adults.</p><p><strong>Renal Impairment:</strong>&nbsp;In patients with renal impairment who have creatinine clearance less than 30ml/min, the dosage of clarithromycin should be reduced to one half of the normal recommended dose.</p><p><strong>Preparation for Use:</strong></p><p>See section 6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to macrolide antibiotic drugs or to any of the excipients listed in section 6.1.
Concomitant administration of clarithromycin and ergot alkaloids (e.g. ergotamine or
dihydroergotamine) is contraindicated, as this may result in ergot toxicity (see sections 4.4
and 4.5).
Concomitant administration of clarithromycin and oral midazolam is contraindicated (see
section 4.5).
Concomitant administration of clarithromycin and lomitapide is contraindicated (see section
4.5).
Concomitant administration of clarithromycin and any of the following drugs is
contraindicated: astemizole, cisapride, domperidone, pimozide and terfenadine as this may
result in QT prolongation and cardiac arrhythmias, including ventricular tachycardia,
ventricular fibrillation, and torsades de pointes (see section 4.4 and 4.5).
Clarithromycin should not be given to patients with history of QT prolongation (congenital or
documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades
de pointes (see sections 4.4 and 4.5).
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors
(statins) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), due to the
increased risk of myopathy, including rhabdomyolysis (See section 4.5).
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients taking
colchicine (see sections 4.4 and 4.5).
Clarithromycin should not be given to patients with electrolyte disturbances (hypokalaemia or
hypomagnesaemia, due to the risk of prolongation of the QT interval).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in
combination with renal impairment.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without carefully<br />weighing the benefits against risk, particularly during the first three months of pregnancy (see<br />section 4.6).<br />Clarithromycin is principally metabolised by the liver. Therefore, caution should be exercised<br />in administering this antibiotic to patients with impaired hepatic function.<br />Caution should also be exercised when administering clarithromycin to patients with<br />moderate to severe renal impairment (see section 4.2).<br />Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic<br />hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic<br />dysfunction may be severe and is usually reversible. Cases of fatal hepatic failure (see section<br />4.8) have been reported. Some patients may have had pre-existing hepatic disease or may<br />have been taking other hepatotoxic medicinal products. Patients should be advised to stop<br />treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as<br />anorexia, jaundice, dark urine, pruritus, or tender abdomen.<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents, including<br />macrolides, and may range in severity from mild to life-threatening. Clostridium difficileassociated<br />diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents<br />including clarithromycin, and may range in severity from mild diarrhoea to fatal colitis.<br />Treatment with antibacterial agents alters the normal flora of the colon, which may lead to<br />overgrowth of C. difficile. CDAD must be considered in all patients who present with<br />diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been<br />reported to occur over two months after the administration of antibacterial agents. Therefore,<br />discontinuation of clarithromycin therapy should be considered regardless of the indication.<br />Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting<br />peristalsis should be avoided.<br />There have been post-marketing reports of colchicine toxicity with concomitant use of<br />clarithromycin and colchicine, especially in the elderly, some of which occurred in patients<br />with renal insufficiency. Deaths have been reported in some such patients (see section 4.5).<br />Concomitant administration of clarithromycin and colchicine is contraindicated (see section<br />4.3).<br />Caution is advised regarding concomitant administration of clarithromycin and<br />triazolobenzodiazepines, such as triazolam, and intravenous or oromucosal midazolam (see<br />section 4.5).<br />Cardiovascular Events:<br />Prolongation of the QT interval, reflecting effects on cardiac repolarisation imparting a risk of<br />developing cardiac arrhythmia and torsades de pointes, have been seen in patients treated<br />with macrolides including clarithromycin (see section 4.8). Due to increased risk of QT<br />prolongation and ventricular arrhythmias (including torsades de pointes), the use of<br />clarithromycin is contraindicated: in patients taking any of astemizole, cisapride,<br />domperidone, pimozide and terfenadine; in patients who have electrolyte disturbances such as<br />hypomagnesaemia or hypokalaemia; and in patients with a history of QT prolongation or<br />ventricular cardiac arrhythmia (see section 4.3).<br />Carefully consider the balance of benefits and risks before prescribing clarithromycin for any<br />patients taking hydroxychloroquine or chloroquine, because of the potential for an increased<br />risk of cardiovascular events and cardiovascular mortality (see section 4.5).<br />Furthermore, clarithromycin should be used with caution in the following:</p><p>&bull; Patients with coronary artery disease, severe cardiac insufficiency, conduction<br />disturbances or clinically relevant bradycardia;<br />&bull; Patients concomitantly taking other medicinal products associated with QT prolongation<br />other than those which are contraindicated<br />Epidemiological studies investigating the risk of adverse cardiovascular outcomes with<br />macrolides have shown variable results. Some observational studies have identified a rare<br />short-term risk of arrhythmia, myocardial infarction and cardiovascular mortality associated<br />with macrolides including clarithromycin. Consideration of these findings should be balanced<br />with treatment benefits when prescribing clarithromycin.<br />Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to macrolides, it<br />is important that sensitivity testing be performed when prescribing clarithromycin for<br />community-acquired pneumonia. In hospital-acquired pneumonia, clarithromycin should be<br />used in combination with additional appropriate antibiotics.<br />Skin and soft tissue infections of mild to moderate severity: These infections are most often<br />caused by Staphylococcus aureus and Streptococcus pyogenes, both of which may be resistant<br />to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where<br />beta&ndash;lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin,<br />may be the drug of first choice. Currently, macrolides are only considered to play a role in<br />some skin and soft tissue infections, such as those caused by Corynebacterium minutissimum,<br />acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.<br />In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe cutaneous<br />adverse reactions (SCAR) (e.g. Acute generalised exanthematous pustulosis (AGEP),<br />Stevens-Johnson Syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and<br />systemic symptoms (DRESS)), clarithromycin therapy should be discontinued immediately<br />and appropriate treatment should be urgently initiated.<br />Clarithromycin should be used with caution when administered concurrently with medications<br />that induce the cytochrome CYP3A4 enzyme (see section 4.5).<br />HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with lovastatin<br />or simvastatin is contraindicated (see section 4.3). Caution should be exercised when<br />prescribing clarithromycin with other statins. Rhabdomyolysis has been reported in patients<br />taking clarithromycin and statins. Patients should be monitored for signs and symptoms of<br />myopathy.<br />In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is<br />recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not<br />dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. (See section 4.5).<br />Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin and oral<br />hypoglycaemic agents (such as sulphonylurias) and/or insulin can result in significant<br />hypoglycaemia. Careful monitoring of glucose is recommended (see section 4.5).<br />Oral anticoagulants: There is a risk of serious haemorrhage and significant elevations in<br />International Normalized Ratio (INR) and prothrombin time when clarithromycin is coadministered<br />with warfarin (see section 4.5). INR and prothrombin times should be frequently<br />monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.<br />Caution should be exercised when clarithromycin is co-administered with direct acting oral<br />anticoagulants such as dabigatran, rivaroxaban and apixaban, particularly to patients at high<br />risk of bleeding (see section 4.5).&nbsp;</p><p>Long-term use may, as with other antibiotics, result in colonisation with increased numbers of<br />non-susceptible bacteria and fungi. If superinfections occur, appropriate therapy should be<br />instituted.<br />Attention should also be paid to the possibility of cross resistance between clarithromycin and<br />other macrolide drugs, as well as lincomycin and clindamycin. Excipients<br />This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say<br />essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarithromycin use in patients who are receiving theophylline may be associated with an<br />increase of serum theophylline concentrations. Monitoring of serum theophylline<br />concentrations should be considered for patients receiving high doses of theophylline or with<br />baseline concentrations in the upper therapeutic range. In two studies in which theophylline<br />was administered with clarithromycin (a theophylline sustained-release formulation was<br />dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the<br />steady-state levels of Cmax, Cmin, and the area under the serum concentration time curve<br />(AUC) of theophylline increased about 20%.<br />Coadministration of clarithromycin with ranitidine bismuth citrate resulted in increased<br />plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations<br />(48%), and increased 14-hydroxy-clarithromycin plasma concentrations (31%). These effects<br />are clinically insignificant.<br />Spontaneous reports in the post-marketing period suggest that concomitant administration of<br />clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants.<br />Prothrombin times should be carefully monitored while patients are receiving clarithromycin<br />and oral anticoagulants simultaneously.<br />The concomitant use of strong CYP3A4 inhibitors is contraindicated with ivabradine.<br />Examples of strong CYP3A4 inhibitor include macrolide antibiotics (e.g., clarithromycin,<br />telithromycin).<br />The concomitant use of transdermal fentanyl with all CYP3A4 inhibitors (such as<br />clarithromycin) may result in an increase in fentanyl plasma concentrations, which could<br />increase or prolong adverse drug effects and may cause potentially fatal respiratory<br />depression. Carefully monitor patients receiving Fentanyl and any CYP3A4 inhibitor for<br />signs of respiratory depression for an extended period of time and adjust the dosage if<br />warranted.<br />CYP3A inhibitors such as clarithromycin may result in increased exposure to nifedipine when<br />co-administered. Careful monitoring and dose adjustment may be necessary; consider<br />initiating nifedipine at the lowest dose available if given concomitantly.<br /><strong>The use of the following drugs is strictly contraindicated due to the potential for severe<br />drug interaction effects:&nbsp;</strong></p><p><u>Astemizole, cisapride, domperidone, pimozide, and terfenadine:</u><br />Elevated cisapride levels have been reported in patients receiving clarithromycin and<br />cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias<br />including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar<br />effects have been observed in patients taking clarithromycin and pimozide concomitantly (see<br />section 4.3).<br />Macrolides have been reported to alter the metabolism of terfenadine resulting in increased<br />levels of terfenadine which has occasionally been associated with cardiac arrhythmias, such<br />as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes<br />(see section 4.3). In one study in 14 healthy volunteers, the concomitant administration of<br />clarithromycin and terfenadine resulted in 2- to 3-fold increase in the serum level of the acid<br />metabolite of terfenadine and in prolongation of the QT interval which did not lead to any<br />clinically detectable effect. Similar effects have been observed with concomitant<br />administration of astemizole and other macrolides.<br /><u>Ergot alkaloids:</u><br />Post-marketing reports indicate that co-administration of clarithromycin with ergotamine or<br />dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm,<br />and ischaemia of the extremities and other tissues including the central nervous system.<br />Concomitant administration of clarithromycin and ergot alkaloids is contraindicated (see<br />section 4.3).<br /><u>Oral Midazolam</u><br />When midazolam was co-administered with clarithromycin tablets (500 mg twice daily),<br />midazolam AUC was increased 7-fold after oral administration of midazolam. Concomitant<br />administration of oral midazolam and clarithromycin is contraindicated (see section 4.3).<br /><u>HMG-CoA Reductase Inhibitors (statins)</u><br />Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see 4.3)<br />as these statins are extensively metabolized by CYP3A4 and concomitant treatment with<br />clarithromycin increases their plasma concentration, which increases the risk of myopathy,<br />including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients taking<br />clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be<br />avoided, therapy with lovastatin or simvastatin must be suspended during the course of<br />treatment.<br />Caution should be exercised when prescribing clarithromycin with statins. In situations where<br />the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to<br />prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on<br />CYP3A metabolism (e.g. fluvastatin) can be considered. Patients should be monitored for<br />signs and symptoms of myopathy.<br /><strong>Effects of Other Medicinal Products on Clarithromycin</strong><br />Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital,<br />St John&rsquo;s wort) may induce the metabolism of clarithromycin. This may result in subtherapeutic<br />levels of clarithromycin leading to reduced efficacy. Furthermore, it might be<br />necessary to monitor the plasma levels of the CYP3A inducer, which could be increased<br />owing to the inhibition of CYP3A by clarithromycin (see also the relevant product<br />information for the CYP3A4 inducer administered). Concomitant administration of rifabutin<br />and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum<br />levels together with an increased risk of uveitis.</p><p>The following drugs are known or suspected to affect circulating concentrations of<br />clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments<br />may be required.<br /><u>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine</u><br />Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine,<br />rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and<br />thus lower the plasma levels of clarithromycin, while increasing those of 14-OHclarithromycin,<br />a metabolite that is also microbiologically active. Since the microbiological<br />activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the<br />intended therapeutic effect could be impaired during concomitant administration of<br />clarithromycin and enzyme inducers.<br /><u>Etravirine</u><br />Clarithromycin exposure was decreased by etravirine; however, concentrations of the active<br />metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has<br />reduced activity against Mycobacterium avium complex (MAC), overall activity against this<br />pathogen may be altered; therefore alternatives to clarithromycin should be considered for the<br />treatment of MAC.<br /><u>Fluconazole</u><br />Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice<br />daily to 21 healthy volunteers led to increases in the mean steady-state minimum<br />clarithromycin concentration (Cmin) and area under the curve (AUC) of<br />33% and 18% respectively. Steady state concentrations of the active metabolite 14-OHclarithromycin<br />were not significantly affected by concomitant administration of fluconazole.<br />No clarithromycin dose adjustment is necessary.<br /><u>Ritonavir</u><br />A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200<br />mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked<br />inhibition of the metabolism of clarithromycin. The clarithromycin Cmax increased by 31%,<br />Cmin increased 182% and AUC increased by 77% with concomitant administration of<br />ritonavir. An essentially complete inhibition of the formation of 14-OH-clarithromycin was<br />noted. Because of the large therapeutic window for clarithromycin, no dosage reduction<br />should be necessary in patients with normal renal function. However, for patients with renal<br />impairment, the following dosage adjustments should be considered: For patients with CLCR<br />30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with<br />CLCR &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of<br />clarithromycin greater than 1 g /day should not be co-administered with ritonavir.<br />Similar dose adjustments should be considered in patients with reduced renal function when<br />ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including<br />atazanavir and saquinavir (see section below, Bi-directional drug interactions).<br /><strong>Effect of Clarithromycin on Other Medicinal Products</strong><br /><u>CYP3A-based interactions</u><br />Co-administration of clarithromycin, which is to inhibit CYP3A, and a drug primarily<br />metabolised by CYP3A may be associated with elevations in drug concentrations that could<br />increase or prolong both therapeutic and adverse effects of the concomitant drug.<br />The use of clarithromycin is contraindicated in patients receiving the CYP3A substrates<br />astemizole, cisapride, domperidone, pimozide and terfenadine due to the risk of QT&nbsp;prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular<br />fibrillation, and torsades de pointes (see sections 4.3 and 4.4).<br />The use of clarithromycin is also contraindicated with ergot alkaloids, oral midazolam, HMG<br />CoA reductase inhibitors metabolised mainly by CYP3A4 (e.g. lovastatin and simvastatin),<br />colchicine, ticagrelor and ranolazine (see section 4.3).<br />Concomitant administration of clarithromycin with lomitapide is contraindicated due to the<br />potential for markedly increased transaminases (see section 4.3).<br />Caution is required if clarithromycin is co-administered with other drugs known to be CYP3A<br />enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g.<br />carbamazepine) and/or the substrate is extensively metabolised by this enzyme. Dosage<br />adjustments may be considered, and when possible, serum concentrations of drugs primarily<br />metabolised by CYP3A should be monitored closely in patients concurrently receiving<br />clarithromycin. Drugs or drug classes that are known or suspected to be metabolised by the<br />same CYP3A isozyme include (but this list is not comprehensive) alprazolam,<br />carbamazepine, cilostazole, ciclosporin, disopyramide, ibrutinib, methadone,<br />methylprednisolone, midazolam (intravenous), omeprazole, oral anticoagulants (e.g. warfarin,<br />rivaroxaban, apixaban), atypical antipsychotics (e.g. quetiapine), quinidine, rifabutin,<br />sildenafil, sirolimus, tacrolimus, triazolam and vinblastine.<br />Drugs interacting by similar mechanisms through other isozymes within the cytochrome P450<br />system include phenytoin, theophylline and valproate.<br /><u>Antiarrhythmics</u><br />There have been post-marketing reports of torsades de pointes occurring with the concurrent<br />use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be<br />monitored for QT prolongation during co-administration of clarithromycin with these drugs.<br />Serum levels of quinidine and disopyramide should be monitored during clarithromycin<br />therapy.<br />There have been post marketing reports of hypoglycemia with the concomitant administration<br />of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored<br />during concomitant administration of clarithromycin and disopyramide.<br /><u>Oral hypoglycemic agents/Insulin</u><br />With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition of CYP3A<br />enzyme by clarithromycin may be involved and could cause hypoglycaemia when used<br />concomitantly. Careful monitoring of glucose is recommended.<br /><u>Omeprazole</u><br />Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40 mg<br />daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were<br />increased (Cmax, AUC0-24, and t1/2 increased by 30%, 89%, and 34%, respectively), by the<br />concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2<br />when omeprazole was administered alone and 5.7 when omeprazole was co-administered with<br />clarithromycin.<br /><u>Direct acting oral anticoagulants (DOACs)</u><br />The DOAC dabigatran is a substrate for the efflux transporter P-gp. Rivaroxaban and<br />apixaban are metabolised via CYP3A4 and are also substrates for P-gp. Caution should be<br />exercised when clarithromycin is co-administered with these agents particularly to patients at<br />high risk of bleeding (see section 4.4).</p><p><u>Sildenafil, tadalafil and vardenafil</u><br />Each of these phosphodiesterase inhibitors is metabolised, at least in part, by CYP3A, and<br />CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of<br />clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased<br />phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages<br />should be considered when these drugs are co-administered with clarithromycin.<br /><u>Theophylline, carbamazepine</u><br />Results of clinical studies indicate that there was a modest but statistically significant (p&le;<br />0.05) increase of circulating theophylline or carbamazepine levels when either of these drugs<br />were administered concomitantly with clarithromycin. Dose reduction may need to be<br />considered.<br /><u>Tolterodine</u><br />The primary route of<u> </u>metabolism for tolterodine is via the 2D6 isoform of cytochrome P450<br />(CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway<br />of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in<br />significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage<br />may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the<br />CYP2D6 poor metaboliser population.<br /><u>Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)</u><br />When midazolam was co-administered with clarithromycin tablets (500 mg twice daily),<br />midazolam AUC was increased 2.7-fold after intravenous administration of midazolam. If<br />intravenous midazolam is co-administered with clarithromycin, the patient must be closely<br />monitored to allow dose adjustment. Drug delivery of midazolam via oromucosal route,<br />which could bypass pre-systemic elimination of the drug, will likely result in a similar<br />interaction to that observed after intravenous midazolam rather than oral administration. The<br />same precautions should also apply to other benzodiazepines that are metabolised by CYP3A,<br />including triazolam and alprazolam. For benzodiazepines which are not dependent on CYP3A<br />for their elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction<br />with clarithromycin is unlikely.<br />There have been post-marketing reports of drug interactions and central nervous system<br />(CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin<br />and triazolam. Monitoring the patient for increased CNS pharmacological effects is<br />suggested.<br /><strong>Other drug interactions</strong><br /><u>Colchicine</u><br />Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp).<br />Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When<br />clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by<br />clarithromycin may lead to increased exposure to colchicine. (see section 4.3 and 4.4).<br /><u>Digoxin</u><br />Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp).<br />Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered<br />together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin.<br />Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin<br />concomitantly have also been reported in post marketing surveillance. Some patients have<br />shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias.<br />Serum digoxin concentrations should be carefully monitored while patients are receiving<br />digoxin and clarithromycin simultaneously.<br />Zidovudine</p><p>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV-infected<br />adult patients may result in decreased steady-state zidovudine concentrations. Because<br />clarithromycin appears to interfere with the absorption of simultaneously administered oral<br />zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin<br />and zidovudine to allow for a 4-hour interval between each medication. This interaction does<br />not appear to occur in paediatric HIV-infected patients taking clarithromycin suspension with<br />zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is<br />administered via intravenous infusion.<br /><u>Phenytoin and Valproate</u><br />There have been spontaneous or published reports of interactions of CYP3A inhibitors,<br />including clarithromycin with drugs not thought to be metabolised by CYP3A (e.g. phenytoin<br />and valproate). Serum level determinations are recommended for these drugs when<br />administered concomitantly with clarithromycin. Increased serum levels have been reported.<br /><u>Hydroxychloroquine and Chloroquine</u><br />Observational data have shown that co-administration of azithromycin with<br />hydroxychloroquine in patients with rheumatoid arthritis is associated with an increased risk<br />of cardiovascular events and cardiovascular mortality. Because of the potential for a similar<br />risk with other macrolides when used in combination with hydroxychloroquine or<br />chloroquine, careful consideration should be given to the balance of benefits and risks before<br />prescribing clarithromycin for any patients taking hydroxychloroquine or chloroquine.<br /><strong>Bi-directional drug interactions</strong><br /><u>Atazanavir</u><br />Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is<br />evidence of a bi-directional drug interaction. Co-administration of clarithromycin (500 mg<br />twice daily) with atazanavir (400 mg once daily) resulted in a 2-fold increase in exposure to<br />clarithromycin and a 70% decrease in exposure to 14-OH-clarithromycin, with a 28%<br />increase in the AUC of atazanavir. Because of the large therapeutic window for<br />clarithromycin, no dosage reduction should be necessary in patients with normal renal<br />function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min),<br />the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance<br />&lt;30 mL/min, the dose of clarithromycin should be decreased by 75% using an appropriate<br />clarithromycin formulation. Doses of clarithromycin greater than 1000 mg per day should not<br />be co-administered with protease inhibitors.<br /><u>Calcium Channel Blockers</u><br />Caution is advised regarding the concomitant administration of clarithromycin and calcium<br />channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine, diltiazem) due to the<br />risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel<br />blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic<br />acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.<br /><u>Itraconazole</u><br />Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a<br />bidirectional drug interaction. Clarithromycin may increase the plasma levels of itraconazole,<br />while itraconazole may increase the plasma levels of clarithromycin. Patients taking<br />itraconazole and clarithromycin concomitantly should be monitored closely for signs or<br />symptoms of increased or prolonged pharmacologic effect.<br /><u>Saquinavir</u><br />Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is<br />evidence of a bi-directional drug interaction. Concomitant administration of clarithromycin<br />(500 mg twice daily) and saquinavir (soft gelatine capsules, 1200 mg three times daily) to 12&nbsp;healthy volunteers resulted in steady-state AUC and Cmax values of saquinavir which were<br />177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and Cmax<br />values were approximately 40% higher than those seen with clarithromycin alone. No dose<br />adjustment is required when the two drugs are co-administered for a limited time at the<br />doses/formulations studied. Observations from drug interaction studies using the soft gelatin<br />capsule formulation may not be representative of the effects seen using the saquinavir hard<br />gelatine capsule. Observations from drug interaction studies performed with saquinavir alone<br />may not be representative of the effects seen with saquinavir/ritonavir therapy. When<br />saquinavir is co-administered with ritonavir, consideration should be given to the potential<br />effects of ritonavir on clarithromycin (see section 4.5: Ritonavir).<br />Patients taking oral contraceptives should be warned that if diarrhoea, vomiting or<br />breakthrough bleeding occur there is a possibility of contraceptive failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of clarithromycin for use during pregnancy has not been established. Based on<br />variable results obtained from animal studies and experience in humans, the possibility of<br />adverse effects on embryofoetal development cannot be excluded. Some observational studies<br />evaluating exposure to clarithromycin during the first and second trimester have reported an<br />increased risk of miscarriage compared to no antibiotic use or other antibiotic use during the<br />same period. The available epidemiological studies on the risk of major congenital<br />malformations with use of macrolides including clarithromycin during pregnancy provide<br />conflicting results. Therefore, use during pregnancy is not advised without carefully weighing<br />the benefits against risks (see section 5.3).<br />Breast-feeding<br />The safety of clarithromycin for using during breast-feeding of infants has not been<br />established. Clarithromycin is excreted into human breast milk in small amounts. It has been<br />estimated that an exclusively breastfed infant would receive about 1.7% of the maternal<br />weight-adjusted dose of clarithromycin.<br />Fertility<br />In the rat, fertility studies have not shown any evidence of harmful effects (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines.<br />The potential for dizziness, vertigo, confusion and disorientation, which may occur with<br />the medication, should be taken into account before patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>a. Summary of the safety profile</em></strong></p><p>The most frequent and common adverse reactions related to clarithromycin therapy for both adult and paediatric populations are abdominal pain, diarrhoea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics (see section b of section 4.8).</p><p>There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without pre-existing mycobacterial infections.</p><p><strong><em>b. Tabulated summary of adverse reactions</em></strong></p><p>The following table displays adverse reactions reported in clinical trials and from post-marketing experience with clarithromycin immediate-release tablets, granules for oral suspension, powder for solution for injection, extended-release tablets and modified-release tablets.</p><p>The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt; 1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very common</p><p>&ge;1/10</p></td><td style="vertical-align:top"><p>Common</p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge;1/1,000 to &lt; 1/100</p></td><td style="vertical-align:top"><p>Not Known*</p><p>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cellulitis<sup>1</sup>, candidiasis<strong>,</strong>&nbsp;gastroenteritis<sup>2</sup>, infection<sup>3</sup>, vaginal infection</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis, erysipelas,</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia, neutropenia<sup>4</sup>, thrombocythaemia<sup>3</sup>, eosinophilia<sup>4</sup></p></td><td style="vertical-align:top"><p>Agranulocytosis, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>1</sup>, hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactic reaction. angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia, decreased appetite</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, nervousness<sup>3</sup></p></td><td style="vertical-align:top"><p>Psychotic disorder, confusional state<sup>5</sup>, depersonalisation, depression, disorientation, hallucination, abnormal dreams, mania</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dysgeusia, headache, taste perversion</p></td><td style="vertical-align:top"><p>Loss of consciousness<sup>1</sup>, dyskinesia<sup>1</sup>, dizziness, somnolence<sup>5</sup>, tremor</p></td><td style="vertical-align:top"><p>Convulsion, ageusia, parosmia, anosmia, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo, hearing impaired, tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cardiac arrest<sup>1</sup>, atrial fibrillation<sup>1</sup>, electrocardiogram QT prolonged, extrasystoles<sup>1</sup>, palpitations</p></td><td style="vertical-align:top"><p>Torsades de pointes, ventricular tachycardia, ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vasodilation<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorder</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthma<sup>1</sup>, epistaxis<sup>2</sup>, pulmonary embolism<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea, vomiting, dyspepsia, nausea, abdominal pain</p></td><td style="vertical-align:top"><p>Oesophagitis<sup>1</sup>, gastrooesophageal reflux disease<sup>2</sup>, gastritis, proctalgia<sup>2</sup>, stomatitis, glossitis, abdominal distension<sup>4</sup>, constipation, dry mouth, eructation, flatulence,</p></td><td style="vertical-align:top"><p>Pancreatitis acute, tongue discolouration, tooth discolouration</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Cholestasis<sup>4</sup>, hepatitis<sup>4</sup>, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>Hepatic failure, jaundice hepatocellular</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash, hyperhidrosis</p></td><td style="vertical-align:top"><p>Dermatitis bullous<sup>1</sup>, pruritus, urticaria, rash maculo-papular<sup>3</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), acne</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasms<sup>3</sup>, musculoskeletal stiffness<sup>1</sup>, myalgia<sup>2</sup></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>2,6</sup>, myopathy</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased<sup>1</sup>, blood urea increased<sup>1</sup></p></td><td style="vertical-align:top"><p>Renal failure, nephritis interstitial</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site phlebitis<sup>1</sup></p></td><td style="vertical-align:top"><p>Injection site pain<sup>1</sup>, injection site inflammation<sup>1</sup></p></td><td style="vertical-align:top"><p>Malaise<sup>4</sup>, pyrexia<sup>3</sup>, asthenia, chest pain<sup>4</sup>, chills<sup>4</sup>, fatigue<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Albumin globulin ratio abnormal<sup>1</sup>, blood alkaline phosphatase increased<sup>4</sup>, blood lactate dehydrogenase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>International normalised ratio increased, prothrombin time prolonged, urine colour abnormal</p></td></tr></tbody></table><p><sup>1&nbsp;</sup>ADRs reported only for the Powder for Solution for Injection formulation</p><p><sup>2</sup>ADRs reported only for the Extended-Release Tablets formulation</p><p><sup>3&nbsp;</sup>ADRs reported only for the Granules for Oral Suspension formulation</p><p><sup>4&nbsp;</sup>ADRs reported only for the Immediate-Release Tablets formulation</p><p><sup>5,6&nbsp;</sup>See section c)</p><p><em>* Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Patient exposure is estimated to be greater than 1 billion patient treatment days for clarithromycin.</em></p><p><strong><em>c. Description of selected adverse reactions</em></strong></p><p>Injection site phlebitis, injection site pain, and injection site inflammation are specific to the clarithromycin intravenous formulation.</p><p>In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested (see section 4.5).</p><p>There have been rare reports of clarithromycin ER tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhoea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic.</p><p>Special population: Adverse Reactions in Immunocompromised Patients (see section e).</p><p><strong><em>d. Paediatric populations</em></strong></p><p>Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension.</p><p>Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p><strong>e.&nbsp;<em>Other special populations</em></strong></p><p><strong><em>Immunocompromised patients</em></strong></p><p>In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness.</p><p>In adult patients, the most frequently reported adverse reactions by patients treated with total daily doses of 1000 mg and 2000mg of clarithromycin were: nausea, vomiting, taste perversion, abdominal pain, diarrhoea, rash, flatulence, headache, constipation, hearing disturbance,&nbsp;<u>Serum Glutamic Oxaloacetic Transaminase</u>&nbsp;(SGOT) and&nbsp;<u>Serum Glutamic Pyruvate Transaminase</u>&nbsp;(SGPT) elevations. Additional low-frequency events included dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated with 1000mg and 2000mg, but were generally about 3 to 4 times as frequent for those patients who received total daily doses of 4000mg of clarithromycin.</p><p>In these immunocompromised patients, evaluations of laboratory values were made by analysing those values outside the seriously abnormal level (i.e. the extreme high or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients who received 1000mg or 2000mg of clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen levels. Slightly higher incidences of abnormal values were noted for patients who received 4000mg daily for all parameters except White Blood Cell.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p><strong>To report any side effect(s):</strong></p><p><strong>-National Pharmacovigilance Center (NPC)</strong></p><p><strong>o Fax: +966-11-205-7662</strong></p><p><strong>o SFDA Call Center: 19999</strong></p><p>o <strong>E-mail: npc.drug@sfda.gov.sa</strong></p><p>o <strong>Website: https://ade.sfda.gov.sa</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin orally can be expected to produce gastro-intestinal symptoms. One patient who had a history of bipolar disorder ingested 8 grams of clarithromycin and showed altered mental status, paranoid behaviour, hypokalaemia and hypoxaemia.</p><p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by haemodialysis or peritoneal dialysis.</p><p>In the case of overdosage, Klacid IV should be discontinued and all other appropriate supportive measures should be instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>ATC Classification:</u></p><p>Pharmacotherapeutic group: Antibacterial for systemic use, macrolide</p><p>ATC-Code: J01FA09</p><p><u>Mode of Action:</u></p><p>Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria.</p><p>The 14-hydroxy metabolite of clarithromycin, a product of parent drug metabolism also has anti-microbial activity. The metabolite is less active than the parent compound for most organisms, including mycobacterium spp. An exception is Haemophilus influenza where the 14-hydroxy metabolite is two-fold more active than the parent compound.</p><p>Klacid IV or Clarithromycin 500 mg/vial Powder for Solution for Injection is usually active against the following organisms in vitro:</p><p><strong>Gram-positive Bacteria:</strong>&nbsp;<em>Staphylococcus aureus&nbsp;</em>(methicillin susceptible);&nbsp;<em>Streptococcus pyogenes&nbsp;</em>(Group A beta-haemolytic streptococci); alpha-haemolytic streptococcus (viridans group);&nbsp;<em>Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.</em></p><p><strong>Gram-negative Bacteria:</strong>&nbsp;<em>Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella pneumophila, Bordetella pertussis, Helicobacter pylori; Campylobacter jejuni.</em></p><p><strong>Mycoplasma:&nbsp;</strong><em>Mycoplasma pneumoniae; Ureaplasma urealyticum.</em></p><p><strong>Other Organisms:</strong>&nbsp;<em>Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae; Chlamydia pneumoniae.</em></p><p><strong>Anaerobes:</strong>&nbsp;Macrolide-susceptible&nbsp;<em>Bacteriodes fragilis; Clostridium perfringens;&nbsp;</em>Peptococcus species; Peptostreptococcus species;&nbsp;<em>Propionibacterium acnes.</em></p><p>Clarithromycin has bactericidal activity against several bacterial strains. These organisms include&nbsp;<em>H. influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Morazella (Brahamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter pylori&nbsp;</em>and Campylobacter spp.</p><p>The activity of clarithromycin against&nbsp;<em>H. pylori&nbsp;</em>is greater at neutral pH than at acid pH.</p><p><strong>Breakpoints</strong></p><p>The following breakpoints have been established by the European Committee for Antimicrobial Susceptibility Testing (EUCAST).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center">Breakpoints (MIC, mg/L)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible (&le;)</strong></p></td><td style="vertical-align:top"><p><strong>Resistant (&gt;)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus spp.</em></p></td><td style="vertical-align:top"><p>1 mg/L</p></td><td style="vertical-align:top"><p>2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus A, B, C and G</em></p></td><td style="vertical-align:top"><p>0.25 mg/L</p></td><td style="vertical-align:top"><p>0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumonia</em></p></td><td style="vertical-align:top"><p>0.25 mg/L</p></td><td style="vertical-align:top"><p>0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Viridans group streptococcus</em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus spp.</em></p></td><td style="vertical-align:top"><p>1 mg/L</p></td><td style="vertical-align:top"><p>32 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>0.25 mg/L</p></td><td style="vertical-align:top"><p>0.5 mg/L&nbsp;<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Helicobacter pylori</em></p></td><td style="vertical-align:top"><p>0.25 mg/L<sup>1</sup></p></td><td style="vertical-align:top"><p>0.5 mg/L</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>&nbsp;The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduces susceptibility.</p><p>&ldquo;IE&quot; indicates that there is insufficient evidence that the species in question is a good target for therapy with the drug.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The microbiologically active metabolite 14-hydroxyclarithromycin is formed by first pass metabolism as indicated by lower bioavailability of the metabolite following IV administration. Following IV administration the blood levels of clarithromycin achieved are well in excess of the MIC&nbsp;<sub>90</sub>s for the common pathogens and the levels of 14-hydroxyclarithromycin exceed the necessary concentrations for important pathogens, e.g.&nbsp;<em>H. influenzae.</em></p><p>The pharmacokinetics of clarithromycin and the 14-hydroxy metabolite are non-linear; steady state is achieved by day 3 of IV dosing. Following a single 500mg IV dose over 60 minutes, about 33% clarithromycin and 11% 14-hydroxyclarithromycin is excreted in the urine at 24 hours.</p><p>Klacid IV 500 mg does not contain tartrazine or other azo dyes, lactose or gluten.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility, Reproduction and Teratogenicity<br />No fertility studies with intravenous (I.V.) administration of clarithromycin have been<br />conducted. Oral fertility and reproduction studies in rats have shown no adverse effects.<br />Intravenous embryo-foetal toxicity studies demonstrated no evidence of embryofoetal toxicity<br />or teratogenicity at maternally toxic dosages up to 160 mg/kg/day in rats (~1.5 times the<br />maximum recommended human dose (MRHD) on a mg/m2 basis) and 30 mg/kg/day in rabbits<br />(~0.6 times the MRHD on a mg/m2 basis). In rabbits, in utero foetal loss occurred at an<br />intravenous dose of 33 mg/m2, which is 17 times less than the MRHD of 618 mg/m2. Oral<br />teratogenicity studies in rats, rabbits and monkeys failed to demonstrate any teratogenicity from&nbsp;clarithromycin at the highest doses tested up to 1.5, 2.4 and 1.5 times the MRHD of 1 g/day<br />P.O. on a mg/m2 basis in the respective species. However, a similar study in Sprague-Dawley<br />rats indicated a low (6%) incidence of cardiovascular abnormalities which appeared to be due<br />to spontaneous expression of genetic changes. Two oral studies in mice revealed a variable<br />incidence (3-30%) of cleft palate at 1000 mg/kg/day (~5 times the MRHD of 1 g/day P.O. on<br />a mg/m2 basis). Embryonic loss was seen in monkeys but only at dose levels clearly toxic to<br />the mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactobionic acid</p><p>Sodium Hydroxide (for pH-adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known. However, Klacid IV 500 mg should only be diluted with the diluents<br />recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months unopened.
The initial solution after reconstitution may be stored for 24 hours between 2 and 8 C (in the
refrigerator)
The final solution after dilution may be stored for 24 hours between 2 and 8 C (in the refrigerator) or
for 6 hours at a temperature below 25 C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at temperature below &nbsp;30&deg; C.</p><p>Store in the original container</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>15ml Ph.Eur. Type I flint glass tubing vial with a 20mm grey halobutyl siliconised lyophilisation stopper with a flip-off cap. Vials are packed in units of 1, 4 and 6. Pack size 500mg.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Klacid Intravenous 500 mg should be administered into one of the larger proximal veins as an IV infusion over 60 minutes, using a solution concentration of about 2mg/ml. Clarithromycin should not be given as a bolus or an intramuscular injection.</p><p>Preparation for Use<br />Reconstitution (Step 1)<br />Prepare the initial solution of Klacid IV 500mg by adding 10 ml of sterile Water for Injection<br />to the 500 mg vial. Shake until the vial contents have dissolved. Use only sterile Water for<br />Injection, as other diluents may cause precipitation during reconstitution. Do not use diluents<br />containing preservatives or inorganic salts. Each ml contains 50 mg clarithromycin.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.<br />Dilution (Step 2)<br />The reconstituted product (500 mg in 10 ml Water for Injection) should be added to a<br />minimum of 250 ml of one of the following diluents before administration: 5% dextrose in<br />Lactated Ringer&#39;s solution, 5% dextrose, Lactated Ringer&#39;s, 5% dextrose in 0.3% sodium<br />chloride, Normosol-M in 5% dextrose, Normosol-R in 5% dextrose, 5% dextrose in 0.45%<br />sodium chloride, and 0.9% sodium chloride.<br />1ml of the infusion solution prepared in this way contains 2mg clarithromycin.<br />For storage conditions after dilution of the medicinal product, see section 6.3.&nbsp;</p><p><strong>IMPORTANT: BOTH DILUENT STEPS (1 and 2) SHOULD BE COMPLETED BEFORE<br />USE.</strong><br />Any unused medicinal product or waste material should be disposed of in accordance with<br />local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing authorisation holder
Abbott Laboratories Limited
Abbott House, Vanwall Business park, 
Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13/05/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>